The ChemDiv’s scientists – in collaboration with their colleagues from ChemRar Group – are working with multiple research and development organizations that specialize in innovative pharmaceuticals. As a result, the ChemDiv researchers can pride themselves in supporting research and development of innovative pharmaceutical products, diagnostics tools as well as new methods for treating oncology disorders, cardiometabolic, and infectious diseases. One of the latest achievements was the development, registration and release of Avifavir for the new coronavirus infection treatment to the international market.
Within the shortest term possible, the ChemDiv specialists developed testing platforms and a set of methods for the synthesis of substances and pharmaceutical formulation. On May 29th, 2020, after all the pre-clinical and clinical studies were completed, the medicine was registered and became available to patients.
Avifavir as the world’s first medicine with Favipiravir as its active agent, was registered for the treatment of the new coronavirus infection. The efficiency of Favipiravir-based medicines has been proven by three independent clinical studies in Russia based on the treatment of 3000 patients with confirmed COVID-19 diagnosis, as well as studies carried out in Japan and other countries.
Avifavir has been registered and is widely used for coronavirus treatment in over 15 countries. In Russia only, the monthly production volume of the medicine is planned to be increased to 1,000,000 packages a month.